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Abstract
Background The cardiovascular safety profile of biologic therapies used for psoriasis is unclear.
Objectives To compare the risk of major cardiovascular events (CVEs; acute coronary syndrome, unstable angina,
myocardial infarction and stroke) in patients with chronic plaque psoriasis treated with adalimumab, etanercept or ustek-
inumab in a large prospective cohort.
Methods Prospective cohort study examining the comparative risk of major CVEs was conducted using the British
Association of Dermatologists Biologics and Immunomodulators Register. The main analysis compared adults with
chronic plaque psoriasis receiving ustekinumab with tumour necrosis-a inhibitors (TNFi: etanercept and adalimumab),
whilst the secondary analyses compared ustekinumab, etanercept or methotrexate against adalimumab. Hazard ratios
(HRs) with 95% confidence intervals (CIs) were calculated using overlap weights by propensity score to balance baseline
covariates among comparison groups.
Results We included 5468 biologic-na€ıve patients subsequently exposed (951 ustekinumab; 1313 etanercept; and
3204 adalimumab) in the main analysis. The secondary analyses also included 2189 patients receiving methotrexate.
The median (p25–p75) follow-up times for patients using ustekinumab, TNFi, adalimumab, etanercept and methotrexate
were as follows: 2.01 (1.16–3.21), 1.93 (1.05–3.34), 1.94 (1.09–3.32), 1.92 (0.93–3.45) and 1.43 (0.84–2.53) years, respec-
tively. Ustekinumab, TNFi, adalimumab, etanercept and methotrexate groups had 7, 29, 23, 6 and 9 patients experienc-
ing major CVEs, respectively. No differences in the risk of major CVEs were observed between biologic therapies
[adjusted HR for ustekinumab vs. TNFi: 0.96 (95% CI 0.41–2.22); ustekinumab vs. adalimumab: 0.81 (0.30–2.17); etaner-
cept vs. adalimumab: 0.81 (0.28–2.30)] and methotrexate against adalimumab [1.05 (0.34–3.28)].
Conclusions In this large prospective cohort study, we found no significant differences in the risk of major CVEs
between three different biologic therapies and methotrexate. Additional studies, with longer term follow-up, are needed
to investigate the potential effects of biologic therapies on incidence of major CVEs.
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Introduction
Psoriasis is a common, chronic inflammatory skin disease affect-
ing over 125 million people worldwide.1 The prevalence of pso-
riasis varies between countries (0.91–8.5%), and recent estimates
suggest that almost 3% of the UK population are affected by the
disease.2,3 Cardiovascular (CV) comorbidities are common
among patients with psoriasis.4 Moreover, CV risk factor screen-
ing of adult patients with psoriasis in primary care has found a
high proportion of patients being sub-optimally treated for
known CV risk factors.5 This can contribute to an increased risk
of major CV events (CVEs) in patients with psoriasis.
Biologic therapies are increasingly used for the treatment of
moderate–severe psoriasis, but their CV safety profile is still
unclear. In recent years, concerns have been raised regarding an
increased CV risk due to the use of anti-interleukin (IL)-12/23
agents after a number of major adverse CVEs s [MACEs;
myocardial infarction (MI), cerebrovascular accident or CV
death] occurred in patients receiving briakinumab [anti-IL-12/
23 agent; Five patients experiencing major adverse CVEs (onset
ranged from 21–55 days) during the induction phase and two
patients experiencing the events on day 131 and 225 during the
maintenance phase] which in part resulted in the discontinua-
tion of the development of this treatment.6–8 A recent meta-ana-
lysis of randomized controlled trials (RCTs) suggested that there
was no significant difference in the risk of MACEs between
licensed biologic therapies and placebo.9 However, the risks were
examined over short periods (10–30 weeks) and participants
included in RCTs tend to have fewer comorbidities than psoria-
sis patients in a real-world setting.9,10 Several cohort studies have
examined the impact of biologic therapies on CVEs in patients
with psoriasis involving a range of different reference treatments
including non-biologic, non-systemic therapies (topical therapy,
phototherapy and climate therapy) or methotrexate.11–15 These
therapies are typically recommended for patients before receiv-
ing biologic therapies. To assess the association between CVEs
and treatments, participants in treatment and reference groups
should have a similar severity of psoriasis since this may
influence the development of CVEs.16 Ideally, biologic therapies
should be directly compared.
The objectives of this study were to directly compare the risk
of major CVEs (acute coronary syndrome, unstable angina, MI
and stroke) in adult patients with chronic plaque psoriasis under
routine care treated with adalimumab, etanercept or ustek-
inumab in a large prospective cohort using the British Associa-
tion of Dermatologists Biologics and Immunomodulators
Register (BADBIR).
Methods
The BADBIR is a large prospective cohort study examining the
long-term safety of biologic therapies in patients with psoriasis. It
compares a cohort of psoriasis patients treated with biologic ther-
apies and a cohort of those treated with conventional systemic
therapies (e.g. methotrexate). Data have been collected on
patients with moderate–severe psoriasis being treated at 160 sec-
ondary care dermatology centres across the UK and the Republic
of Ireland since September 2007. BADBIR was approved by the
NHS Research Ethics Committee North West England (reference
07/MRE08/9) in March 2007, and all patients have provided writ-
ten informed consent for participation. Further details regarding
study design of BADBIR has been published previously.17
Baseline assessments
Baseline data collected at enrolment include patient demo-
graphic characteristics, comorbidities, anthropometric data,
drug therapies and clinical data such as type and severity of pso-
riasis (Psoriasis Area and Severity Index; PASI) by healthcare
professionals using an online database, whilst lifestyle informa-
tion such as smoking and alcohol consumption was collected
directly from patients using a questionnaire.
Follow-up assessments
Data are collected every 6 months for the first 3 years and then
annually. These include information on changes in drug thera-
pies, measures of disease severity, hospitalization and details of
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adverse events (AEs) including the outcomes of interest of this
study. Patient death details are derived from the BADBIR regis-
ter via linkage with the Office of National Statistics mortality
records. AEs are coded using the Medical Dictionary for Regula-
tory Activities (MedDRA) system.18
Study population and exposure
Patients who enrolled in the BADBIR from September 2007 to
October 2016 and had at least 6 months of follow-up data fol-
lowing initiation of treatment were selected for this study. Bio-
logic-na€ıve patients aged at least 18 years old with chronic
plaque psoriasis who had no prior history of major CVEs were
selected for the inclusion in this cohort study. For the main anal-
ysis, patients receiving the first-line originator anti-IL-12/23
agent (ustekinumab) were compared with TNFi (etanercept or
adalimumab) as the reference group. For the secondary analyses,
patients receiving first-line adalimumab (the referent group)
were compared with ustekinumab, etanercept or methotrexate.
Outcome of interest and ascertainment
The outcome of interest was fatal or non-fatal major CVEs
[acute coronary syndrome, unstable angina, MI or stroke
(Table S1, Supporting Information) provides the relevant Med-
DRA outcome codes]. All relevant MedDRA codes or descrip-
tions of events were identified by WR. Both codes and
descriptions were independently reviewed by a clinician with
extensive experience in managing CV disease (MKR) in order to
ascertain the final outcome of the study. To validate all serious
outcomes, the BADBIR staff members asked study sites to con-
firm these events. Moreover, patients experiencing acute coro-
nary syndrome, unstable angina and MI were also collected
information on cardio marker, electrocardiogram, previous his-
tory of CV diseases, the use of thrombolysis and angioplasty and
cardiac intervention, whilst patients experiencing stroke were
also collected information on type of stroke, computed tomogra-
phy scan and history of thrombolysis and atrial fibrillation in
order to confirm these events.
Data analysis
Patients were observed from the date of receiving therapy to
developing the first major CVE or the earliest date of change in
treatment (changing to other biologic therapy in the biologic
cohorts or starting a biologic therapy in the methotrexate
cohort); end of recorded data in the BADBIR; death; or end of
the study follow-up (30 September 2016). Discontinuation of
treatment was defined as a gap in a regimen for more than
90 days. We examined the risk of major CVEs occurring over
two periods: (i) whilst exposed to treatment; and (ii) extending
the exposure effect window until 90 days after the last dose.
Planned secondary analyses included direct comparisons
between the individual biologic therapies and users of
methotrexate.
Descriptive statistics were used to analyse baseline patient char-
acteristics. Frequency (%) and median values [25th percentile
(p25)-75th percentile (p75)] were calculated for categorical and
continuous variables, respectively. To control for imbalances in
patient characteristics between cohorts, we calculated an expo-
sure-specific propensity score as the predicted probability of
receiving the treatment of interest conditional upon the subjects’
baseline covariates using logistic regression models for the pri-
mary analysis and multinomial logistic regression models for the
sensitivity analyses. We included the following covariates: baseline
PASI (the score which was before and closest to the start of the
treatment exposures within 6 months), smoking status (ever/
never), current alcohol drinking (yes/no), alcohol consumption
(units/week), obesity (≥30 kg/m2), age, gender, history of psori-
atic arthritis (PsA), hypertension, diabetes, dyslipidemia, angina,
previous treatment with ciclosporin, acitretin, fumaric acid esters
and methotrexate. Covariate balance between the cohorts before
and after propensity score overlap weighting was assessed using
the expected percentage bias which is the difference in the out-
come owing to the imbalance between each covariate taking into
account the strength of the association between each covariate
and the outcome. A maximum bias of 5% in either direction was
considered an acceptable threshold. After generating propensity
scores, overlap weights which were proportional to the probability
of patients being assigned to the reference groups were calculated
for only patients having predicted probabilities within the com-
mon support range. The common support range was defined as
propensity scores of the treated groups overlapping the propensity
scores of the reference groups.
Multiple imputation was used to address missing data on
baseline PASI score, smoking status, current alcohol drinking,
alcohol consumption and obesity using chained equations of 20
cycles to reduce bias. This method preserved the variability and
uncertainty of missing data and avoids the loss of patients due
to missing data and bias when compared with complete case
analysis.19 The imputation model consisted of exposures, start
year of exposure, log of censoring time for the outcome occur-
ring during drug therapy; and during the extended window per-
iod, and whether patients experienced the outcomes during drug
therapy; and during the extended window period, history of
other heart diseases, concomitant drug therapies including
ciclosporin, acitretin, fumaric acid esters and methotrexate; and
the other covariates included in the propensity score model for
the main analysis whilst the sensitivity analyses did not include
concomitant methotrexate.
For each comparison (ustekinumab vs. TNFi for the primary
analysis; and ustekinumab, etanercept or methotrexate vs. adali-
mumab for the secondary analyses) and for all outcomes, we cal-
culated incidence rates (IRs), IR ratios, unadjusted, age and sex
adjusted and overlap weighed hazard ratio (HRs) with 95% con-
fidence intervals (CIs). We assessed the proportional hazards
assumption by examining Schoenfeld residuals and confirming
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that it was not violated. All analyses were performed using Stata
14 (StataCorp LP, College Station, Texas, USA).
Results
A total of 5468 patients were included in the main analysis [anti-
IL-12/23 agent (ustekinumab): 951 and TNFi (adalimumab and
etanercept): 4517; Fig. 1]. Patients in the ustekinumab group
were more likely to be obese, but less likely to have either a his-
tory of PsA, currently drink alcohol or concomitantly receive
methotrexate therapy, as shown in Table 1. The median (p25
and p75) follow-up times for patients taking individual therapies
were as follows: ustekinumab 1.76 (0.92–2.96) years and TNFi
1.69 (0.81–3.10) years for the analysis of events occurring during
drug therapy; and ustekinumab 2.01 (1.16–3.21) years and TNFi
1.93 (1.05–3.34) years for the analysis of events occurring during
the extended exposure window period.
Seven patients in the ustekinumab group experienced a major
CVE during treatment with no additional patients experiencing
Patients enrolled in the BADBIR at data 
snapshot October 2016 
(n = 12 848)
Patients on a biologic or conventional 
systemic therapy 
(n = 11 009)
Patients with ≥ 1 follow-up visit 
(n = 9 713)
Patients with chronic plaque psoriasis 
(n = 9 574)
Patients aged ≥ 18 years old
(n = 9 533)
Biologic naïve patients
(n = 8 050) 
Patients on an eligible psoriasis treatment 
(n = 7 910)
Patients without previous outcomes 
(n = 7 657)
Included patients 
for 
the main analysis
n = 5 468 
(TNFi n = 4 517 and, 
ustekinumab n = 951)
Included patients for the sensitivity 
analysis
n = 7 657 
(ustekinumab, n = 951; etanercept, 
n = 1 313, adalimumab, n = 3 204 and 
methotrexate, n = 2 189)
Excluded patients without biologic 
or conventional systemic therapies 
(n = 1 839)
Excluded patients without follow-up 
data (n = 1 296)
Excluded patients without chronic 
plaque psoriasis
(n = 139)
Excluded patients aged 
< 18 years old (n = 41)
Excluded non-biologic naïve patients
(n = 1 483)
Excluded patients with ineligible 
psoriasis treatment 
(n = 140)
Excluded patients with previous 
outcomes
(n = 253)
Excluded patients on methotrexate 
(n = 2 189)
Figure 1 Patient selection.
© 2019 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd
on behalf of European Academy of Dermatology and Venereology.
JEADV 2020, 34, 769–778
772 Rungapiromnan et al.
such an outcome within 90 days after the last dose. For the TNFi
cohort, 24 and 29 patients experienced major CVEs during drug
therapy and during the extended exposure window period,
respectively. The median times to onset of the major CVEs in
both groups were about 1 year during either drug therapy or the
extended exposure window period (Table 2).
Incidence rates of major cardiovascular events
The IRs of major CVEs associated with ustekinumab therapy for
both periods were numerically but not statistically significantly
higher than those associated with TNFi. Crude IRs (95% CI) in
the ustekinumab and TNFi groups were 3.61 (1.72–7.58) and
2.46 (1.65–3.67) per 1000 patient-years, respectively, for the out-
come during drug therapy; and 3.23 (1.54–6.77) and 2.67 (1.86–
3.84) per 1000 patient-years, respectively, for the extended expo-
sure window period (Table 2).
Comparative risks of major cardiovascular events
The unadjusted and age-sex adjusted HRs showed no difference
in the risk of major CVEs between patients treated with ustek-
inumab and TNFi therapies. In the propensity score-adjusted
analysis, there was similarly no difference in the risk of major
Table 1 Baseline characteristics of patients receiving anti-interleukin-12/23 agent (ustekinumab) or TNFi (etanercept and adalimumab)
Characteristics Ustekinumab TNFi
Number of patients (N = 5468) 951 4517
Age (years; N = 5468) 45 (35–54) (n = 951) 44 (35.2–53) (n = 4517)
Sex, male (N = 5468) 590 (62.0) (n = 951) 2645 (58.6) (n = 4517)
Ethnicity, white (N = 5461) 853 (89.7) (n = 951) 4157 (92.2) (n = 4510)
BMI (kg/m2; N = 4983) 30.3 (26.2–35.7) (n = 851) 29.4 (25.9–33.8) (n = 4132)
Obese (BMI ≥30 kg/m2) 441 (51.8) (n = 851) 1922 (46.5) (n = 4132)
Ever smoke (yes/no; N = 4885) 599 (66.6) (n = 899) 2541 (63.8) (n = 3986)
Disease durations (years; N = 5417) 19 (11–30) (n = 943) 20 (12–29) (n = 4474)
PASI score (N = 4833) 14.6 (11.2–19.2) (n = 845) 14.1 (11.0–19.3) (n = 3988)
DLQI (N = 2949) 18 (12–24) (n = 460) 18 (13–24) (n = 2489)
Comorbidities
No comorbidities 315 (33.1) 1356 (30.0)
Psoriatic arthritis 134 (14.1) 1035 (22.9)
Hypertension 241 (25.3) 1103 (24.4)
Diabetes mellitus 98 (10.3) 357 (7.9)
Dyslipidemia 98 (10.3) 435 (9.6)
Angina 20 (2.1) 57 (1.3)
Other heart diseases 23 (2.4) 80 (1.8)
Other comorbidities 512 (53.8) 2422 (53.6)
Current alcohol drinking (N = 4899) 593 (65.7) (n = 903) 2854 (71.4) (n = 3996)
Alcohol units per week in patients consuming alcohol (N = 3382) 8 (3–15) (n = 584) 9 (3–16) (n = 2798)
Previous treatment of conventional systemic therapies
Methotrexate 667 (70.1) 3124 (69.2)
Ciclosporin 540 (56.8) 2585 (57.2)
Acitretin 399 (42.0) 2008 (44.5)
Fumaric acid esters 165 (17.4) 879 (19.5)
Concomitant therapies during drug therapy
Methotrexate 120 (12.6) 909 (20.1)
Ciclosporin 71 (7.5) 455 (10.1)
Acitretin 28 (2.9) 163 (3.6)
Fumaric acid esters 13 (1.4) 79 (1.8)
Concomitant therapies during active use of the exposure or window period
Methotrexate 121 (12.7) 946 (20.9)
Ciclosporin 74 (7.8) 491 (10.9)
Acitretin 29 (3.1) 179 (4.0)
Fumaric acid esters 13 (1.4) 87 (1.9)
Data are n (%) or median (25th percentile-75th percentile).
BMI, body mass index; DLQI, Dermatology Life Quality Index; PASI, Psoriasis Area Severity Index; TNFi, tumour necrosis factor-a inhibitors.
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CVEs occurring during both periods (Fig. 2a). The baseline
characteristics of the treatment cohorts were comparable after
applying the overlap weights using the propensity score method
as shown in Fig. 3.
Secondary analyses comparing the risk of major CVEs
associated with individual therapies
A total of 7657 patients were included in the secondary analyses
(ustekinumab, 951; etanercept, 1313; methotrexate, 2189 and:
adalimumab, 3204). The proportions of patients with PsA in the
ustekinumab (14.1%) and methotrexate (8.9%) groups were
lower than in the adalimumab (23.3%) or etanercept (21.9%)
groups, as shown in Table S2 (Supporting Information). The
ustekinumab, etanercept and adalimumab cohorts had longer
durations of follow-up than the methotrexate group (Table 3).
During drug therapy, major CVEs occurred in 7, 5, 7 and 19
patients receiving ustekinumab, etanercept, methotrexate and
adalimumab, respectively; during the extended exposure window
period, major CVEs occurred in 7, 6, 9 and 23 patients, respec-
tively. The IRs associated with exposure to ustekinumab were
numerically higher than those associated with adalimumab and
methotrexate but these differences were not significant. The
median times to onset of major CVEs in all groups and analyses
were about 1 year but etanercept had the longest onset of major
CVEs compared with the other groups (Table 3).
The proportionality test for all comparisons and both analysis
times showed no violation of the proportional hazard assump-
tions. Moreover, the expected percentage bias achieved a good
balance in all analyses, after adjusted for overlap weights by
propensity score (Figs S1–S3, Supporting Information).
There were no significant differences in the risk for major
CVE occurring during drug therapy or the extended exposure
window period when patients using ustekinumab, etanercept or
methotrexate were compared with those using adalimumab as
shown in (Fig. 2b).
Discussion
In this large prospective cohort study, we found no significant
differences in the risk of major CVEs between biologic therapies
in adult patients with chronic plaque psoriasis. Moreover, the
risk of major CVEs for methotrexate was not significantly differ-
ent from adalimumab. These findings are derived from propen-
sity score-adjusted models taking into account a range of
important CV risk factors. Our findings were consistent for sep-
arate analyses comparing the risk of major CVEs both during
therapy and for an extended exposure window period.
Earlier observational studies had a number of differences
which make comparison with our study difficult: notably, differ-
ent comparators and definitions of CV outcomes, including par-
ticipants with prior CVEs in the studies, and not controlling for
some important CV risk factors11–15 (Table S3, Supporting
Information). The results of these previous studies suggested
benefits of biologic therapies in relation to risk of CV outcomes.
One study suggested that TNFi-treated patients (adalimumab,
etanercept and infliximab; n = 9148) had a significantly lower
risk of composite and individual CVEs (MI; stroke or transient
ischaemic attack; or unstable angina) when compared with those
treated with methotrexate (n = 8581).11 In addition, two cohort
studies suggested that TNFi (n1 = 1463 and n2 = 11 410) sig-
nificantly decreased the risk of major adverse CVEs when com-
pared with topical therapies (n = 13 112) and the risk of major
CVEs (MI; stroke or transient ischaemic attack; or unstable ang-
ina; which is different definition than we used in this current
study) when compared with phototherapy (n = 12 433).14,15
Another study defined CVEs as composite MI, stroke and CV
death. It found a significantly lower risk of CVEs in TNFi
(n = 959) and methotrexate (n = 3564)-treated groups, whilst
the risk in those treated with ustekinumab (n = 178) was similar
to those using other therapies (topical, phototherapy and climate
therapy; n = 3961).13 Since the sample size of the ustekinumab
group was very small in this earlier study, it is unlikely that any
difference in the risk of CVEs would be detected for this
Table 2 Incidence rates and incidence rate ratios among patients
receiving anti-interleukin-12/23 agent (ustekinumab) or TNFi (etan-
ercept and adalimumab)
Ustekinumab TNFi
Outcome during drug therapy
Total patient-years 1936.56 9757.22
Patient-years of follow-up
(median, p25–p75)
1.76 (0.92–2.96) 1.69 (0.81–3.10)
Number of major cardiovascular
events
7 24
Incidence rate per 1000 patient-
years (95% CI)
3.61 (1.72–7.58) 2.46 (1.65–3.67)
Incidence rate ratio 1.47 (0.53–3.52) Reference
Duration between the start of
exposure to development of the
outcome (years; median, p25–
p75; only patients experiencing
the outcome)
1.06 (0.59–1.94) 1.19 (0.50–2.14)
Outcome during drug therapy plus grace period (90 days)
Total patient-years 2167.61 10 858.90
Patient-years of follow-up
(median, p25–p75)
2.01 (1.16–3.21) 1.93 (1.05–3.34)
Number of major cardiovascular
events
7 29
Incidence rate per 1000 patient-
years (95% CI)
3.23 (1.54–6.77) 2.67 (1.86–3.84)
Incidence rate ratio 1.21 (0.45–2.82) Reference
Duration between the start of
exposure to development of the
outcome (years; median, p25–
p75; only patients experiencing
the outcome)
1.06 (0.59–1.94) 1.06 (0.47–1.98)
95% CI, 95% confidence interval; p25–p75, 25th percentile-75th percentile;
TNFi, tumour necrosis factor-a inhibitors.
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comparison. In line with our findings, an earlier cohort study
found that patients treated with biologic therapies (including
ustekinumab, adalimumab, etanercept, alefacept and efalizumab;
n = 7682 at enrolment) had a similar risk of CVEs (non-fatal-
MI, non-fatal-stroke and CV death) when compared to those
treated with non-biologic agents (n = 5576 at enrolment).12 A
recent large cohort study compared ustekinumab (n = 9071)
with TNFi (adalimumab, etanercept, infliximab, certolizumab or
golimumab; n = 50 957) among patients with psoriasis or PsA
to examine the risk of atrial fibrillation or major adverse CVEs.20
In line with our findings, this study found no significant
difference in the risk of CVEs outcomes. Of related interest, two
RCTs examining the impact of adalimumab (TNFi) on aortic
vascular inflammation in patients with moderate–severe psoria-
sis also reported that adalimumab did not improve aortic vascu-
lar inflammation after 52 weeks of treatment.21,22
Power calculation is used to inform how well we could char-
acterize nature in the future given in a certain situation and sta-
tistical study design.23 Since this study explored the relationship
between major CVEs and biologic therapies for the treatment of
psoriasis using the real data and there was no significant differ-
ence in the risk of major CVEs for all comparisons, it is pointless
1.44 (0.62 − 3.35)
1.19 (0.52 − 2.71)
1.42 (0.61 − 3.31)
1.16 (0.51 − 2.66)
1.15 (0.49 − 2.74)
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Figure 2 Crude and adjusted hazard ratios (95% confidence interval) for major cardiovascular events associated with different psoriasis
therapies. (a) Comparison of anti-interleukin-12/23 agent (ustekinumab) with tumour necrosis factor-a inhibitors (referent group). (b) Com-
parisons of ustekinumab, etanercept or methotrexate with adalimumab (referent group).
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to calculate post hoc power calculation. It does not yield addi-
tional insights.23
Our study has several important strengths. Firstly, we reduced
potential bias by using a new-user study design for the biologic
cohorts24 and propensity score techniques for examining the
impact of biologic therapies on risk of major CVEs. The
propensity score technique adequately controlled for measured
CV confounders between comparison groups. Secondly, we
excluded patients who had experienced prior major CVEs to fur-
ther minimize bias.
We also acknowledge some study limitations. First, although
we controlled for measured confounders including the most
(a) (b)
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Figure 3 Distribution of confounders between anti-interleukin-12/23 agent (ustekinumab) and tumour necrosis factor-a inhibitors (refer-
ent) patients before creating propensity score and after overlap weighting by propensity score. (a) Outcomes occurring during drug ther-
apy. (b) Outcomes occurring during drug therapy plus grace period (90 days).
Table 3 Incidence rates and incidence rate ratios among patients receiving ustekinumab, etanercept, methotrexate or adalimumab
Ustekinumab Etanercept Methotrexate Adalimumab
Outcome during drug therapy
Total patient-years 1936.56 2905.99 3650.81 6851.23
Patient-years of follow-up (median, p25–p75) 1.76 (0.92–2.96) 1.67 (0.69–3.20) 1.18 (0.59–2.29) 1.69 (0.84–3.07)
Number of major cardiovascular events 7 5 7 19
Incidence rate per 1000 patient-years (95% CI) 3.61 (1.72–7.58) 1.72 (0.72–4.13) 1.92 (0.91–4.02) 2.77 (1.77–4.35)
Incidence rate ratio 1.30 (0.46–3.24) 0.62 (0.18–1.72) 0.69 (0.25–1.72) Reference
Incidence rate ratio 1.89 (0.56–6.30) 0.90 (0.22–3.28) Reference 1.45 (0.58–4.07)
Duration between the start of exposure to
development of the outcome (years; median,
p25–p75; only patients experiencing the outcome)
1.06 (0.59–1.94) 1.29 (1.08–1.82) 0.99 (0.86–1.60) 0.90 (0.46–2.29)
Outcome during drug therapy plus grace period (90 days)
Total patient-years 2167.61 3226.03 4185.94 7632.87
Patient-years of follow-up (median, p25–p75) 2.01 (1.16–3.21) 1.92 (0.93–3.45) 1.43 (0.84–2.53) 1.94 (1.09–3.32)
Number of major cardiovascular events 7 6 9 23
Incidence rate per 1000 patient-years (95% CI) 3.23 (1.54–6.77) 1.86 (0.84–4.14) 2.15 (1.12–4.13) 3.01 (2.00–4.53)
Incidence rate ratio 1.07 (0.39–2.58) 0.62 (0.21–1.56) 0.71 (0.29–1.60) Reference
Incidence rate ratio 1.50 (0.48–4.53) 0.87 (0.25–2.72) Reference 1.40 (0.62–3.44)
Duration between the start of exposure to
development of the outcome (years; median,
p25–p75; only patients experiencing the outcome)
1.06 (0.59–1.94) 1.19 (1.06–1.82) 0.99 (0.86–1.60) 0.90 (0.44–2.29)
95% CI, 95% confidence interval; p25–p75, 25th percentile-75th percentile.
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important CV risk factors, we cannot exclude the effects of resid-
ual confounding due to other unmeasured variables such as
physical activity and dietary factors. The propensity score tech-
nique cannot address this limitation. Second, some aspects of CV
risk factor management may be specific to this national cohort,
and therefore, the results may not be generalizable to patients
managed in different healthcare systems. Third, the small num-
bers of major CVEs and participants and the limited follow-up
may have had an impact on the power for these analyses as seen
in HRs with 95% CIs. Moreover, the impact of biologic therapies
on the risk of major CVEs may change over time. Our findings
may serve as hypothesis generating for future studies. Therefore,
continued surveillance of the risk of major CVEs in more patients
with plaque psoriasis with longer follow-up is needed.
Conclusion
Overall, we found no difference in the risk of major CVEs
between etanercept, adalimumab and ustekinumab in adult
patients with moderate–severe plaque psoriasis following short-
to-medium-term exposure. The impact of biologic therapies or
methotrexate on the risk of major CVEs in patients with psoria-
sis may take longer to manifest. Thus, future comparative stud-
ies with longer follow-up and additional data on CV risk factors
will be helpful for continued surveillance of major CVEs in
patients with psoriasis exposed to biologic therapies.
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